Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread®) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe

NCT02479880 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02479880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02479880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread®) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Terminated
Start date
July 3, 2015
Completion date
April 11, 2018
Enrollment
30 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b